Headlines

Novo Nordisk buys Akero Therapeutics in the US

Published by Global Banking & Finance Review

Posted on October 9, 2025

1 min read

· Last updated: January 21, 2026

Add as preferred source on Google
Novo Nordisk buys Akero Therapeutics in the US
Global Banking & Finance Awards 2026 — Call for Entries

STOCKHOLM (Reuters) -Danish drugmaker Novo Nordisk said on Thursday it had agreed to buy United States based Akero Therapeutics, a clinical-stage company developing innovative treatments for patients

Novo Nordisk buys Akero Therapeutics in the US

Overview of the Acquisition

STOCKHOLM (Reuters) -Danish drugmaker Novo Nordisk said on Thursday it had agreed to buy United States based Akero Therapeutics, a clinical-stage company developing innovative treatments for patients with serious metabolic diseases marked by a high unmet medical need.

Details of the Deal

(Reporting by Anna Ringstrom, editing by Essi Lehto)

Key Takeaways

  • Novo Nordisk has acquired Akero Therapeutics.
  • Akero specializes in treatments for metabolic diseases.
  • The acquisition addresses high unmet medical needs.
  • This move strengthens Novo Nordisk's portfolio.
  • The deal was reported by Reuters.

Frequently Asked Questions

What is an acquisition?
An acquisition is a corporate action in which one company purchases most or all of another company's shares to gain control of that company.
What is a clinical-stage company?
A clinical-stage company is a business that is in the process of developing and testing its products or therapies in clinical trials before they can be marketed.

Tags

Related Articles

More from Headlines

Explore more articles in the Headlines category